Welcom ku Sichuan Hengkang Science and Technology Development Co., Ltd.

Wolemba NS Healthcare Staff Wolemba 16 Meyi 2022

Mounjaro idzaperekedwa m'magulu asanu ndi limodzi, 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, ndi 15mg, pamodzi ndi cholembera cha Lilly cha auto-injector chomwe chimabwera ndi singano yobisika.

Mounjaro ndi GIP ndi GLP-1 receptor agonist.(Ngongole: Lilly USA, LLC.)

Eli Lilly and Company (Lilly) walandila chilolezo ku US Food and Drug Administration (FDA) chifukwa cha jakisoni wake wa Mounjaro (tirzepatide) wochizira matenda amtundu wa 2 mwa akulu.

Mounjaro ndi molekyulu imodzi yomwe imayendetsa mahomoni achilengedwe a incretin insulinotropic polypeptide (GIP) ndi glucagon-like peptide-1 (GLP-1) receptor agonist.

Mankhwalawa amawonetsedwa ngati chithandizo kamodzi pamlungu, chophatikizana ndi zakudya komanso masewera olimbitsa thupi kuti apititse patsogolo kuwongolera kwa glycemic mwa akulu omwe ali ndi matenda amtundu wa 2.

Lilly apereka Mounjaro, woyamba komanso yekhayo wa FDA wovomerezeka GIP ndi GLP-1 receptor agonist, mu Mlingo sikisi, kuphatikiza 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, ndi 15mg.

Kampaniyo ikukonzekera kugulitsa mankhwalawa ku US, limodzi ndi cholembera chake chojambulira chomwe chimabwera ndi singano yobisika yolumikizidwa kale, mkati mwa milungu ingapo.

Purezidenti wa Lilly Diabetes Mike Mason adati: "Lilly ali ndi cholowa chazaka pafupifupi 100 chopititsa patsogolo chisamaliro cha anthu omwe ali ndi matenda a shuga - osakhazikika pazomwe zikuchitika.

"Sitikukhutira kudziwa kuti theka la anthu opitilira 30 miliyoni aku America omwe ali ndi matenda a shuga amtundu wa 2 sakukwaniritsa zomwe akufuna.

"Ndife okondwa kubweretsa Mounjaro, yemwe akuyimira kalasi yatsopano yamankhwala amtundu wa 2 omwe adayambitsidwa pafupifupi zaka khumi ndipo akukwaniritsa cholinga chathu chobweretsa njira zatsopano zothandizira odwala matenda ashuga."

Chivomerezo cha FDA cha Mounjaro chidatengera zotsatira za pulogalamu ya Phase 3 SURPASS yomwe idayamba kumapeto kwa chaka cha 2018, yokhala ndi mayesero asanu apadziko lonse lapansi ndi mayesero awiri achigawo ku Japan.

Pulogalamuyi idawunika mphamvu ndi chitetezo cha Mounjaro 5mg, 10mg ndi 15mg ngati monotherapy, komanso ngati chowonjezera pamankhwala osiyanasiyana osamalidwa amtundu wa 2 shuga.

Mu pulogalamu ya SURPASS, Mounjaro 5mg inachititsa kuti A1C ichepetse ndi 1.8% mpaka 2.1%, ndipo onse a Mounjaro 10mg ndi Mounjaro 15mg adathandizira kuchepetsa 1.7% ndi 2.4% A1C.

Mankhwalawa sanasonyezedwe kuti awonongeke;komabe, omwe adalandira chithandizo ndi Mounjaro ataya 12lb (5mg) mpaka 25lb (15mg) kulemera kwapakati, adatero olimba.

Kusintha kwapang'onopang'ono kwa kulemera kwa thupi kunali chimodzi mwazinthu zazikulu zachiwiri mu maphunziro onse a SURPASS.

Odwala omwe adalandira chithandizo cha Mounjaro adanenanso za zotsatira zoyipa monga nseru, kutsekula m'mimba, kuchepa kwa chidwi, kusanza, kudzimbidwa, dyspepsia, ndi kupweteka kwa m'mimba.

Kuphatikiza apo, Mounjaro amabwera ndi Chenjezo la Boxed za zotupa za C-cell za chithokomiro.Mankhwalawa amatsutsana ndi odwala omwe ali ndi mbiri yakale ya medullary thyroid carcinoma kapena odwala omwe ali ndi Multiple Endocrine Neoplasia syndrome mtundu 2.

Mounjaro sanayesedwe mwa odwala omwe ali ndi mbiri ya kapamba ndipo sanawonetsedwe kuti agwiritsidwe ntchito kwa odwala omwe ali ndi matenda a shuga 1, adatero.Lilly.


Nthawi yotumiza: May-24-2022